BioSpace News Archive

ID Genomics, a Seattle-based company, has invented a dipstick-based, rapid test for simultaneous identification of a large number of genetic variants of SARS-CoV-2 and has just received a National Institutes of Health grant to expedite bringing this test to market.

InDex Pharmaceuticals Holding AB announced that the U.S. Food and Drug Administration has given clearance to start the phase III clinical study CONCLUDE in the United States.

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immune-therapeutics based on Seneca Valley Virus, announced the issuance and allowance of several U.S. patents for TEM8 licensed from Memorial Sloan Kettering Cancer Center.

NeuroVision Imaging Inc. announced it has received an additional investment from the Alzheimer’s Drug Discovery Foundation – the foundation’s second round of funding to NeuroVision this year – to hasten development of a novel blood-based lab test to provide detection and measurement of biomarkers for Alzheimer’s disease and other dementias before clinical onset.

ViewRay, Inc. announced that the clinical team at Amsterdam University Medical Centers has started offering “same-day ablative treatment” using MRIdian SMART for patients who are eligible for single fraction MRI-guided radiation therapy.

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced its 2021 interim results and released an update on the recent progress in clinical development, strategic partnerships, and preparation for commercialization.

Medtronic plc announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021.

NRx Pharmaceuticals, announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock.

Bio-Path Holdings, Inc. announced that the U.S. Food and Drug Administration has reviewed and cleared the Investigational New Drug application for BP1002, the Company’s second drug candidate, for an initial Phase 1/ 1b clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.

AdAlta and Carina Biotech enter a collaboration agreement to develop i-body enabled CAR-T cancer immunotherapies against up to five solid tumour antigen targets